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Abstract
Senile plaque-associated changes in neuronal connectivity such as altered neurite trajectory,
dystrophic swellings, and synapse and dendritic spine loss are thought to contribute to cognitive
dysfunction in Alzheimer’s disease and mouse models. Immunotherapy to remove amyloid beta is
a promising therapy that causes recovery of neurite trajectory and dystrophic neurites over a period
of days. The acute effects of immunotherapy on neurite morphology at a time point when soluble
amyloid has been cleared but dense plaques are not yet affected are unknown. To examine whether
removal of soluble amyloid β (Aβ) has a therapeutic effect on dendritic spines, we explored spine
dynamics within one hour of applying a neutralizing anti Aβ antibody. This acute treatment caused
a small but significant increase in dendritic spine formation in PDAPP brain far from plaques, without
affecting spine plasticity near plaques or average dendritic spine density. These data support the
hypothesis that removing toxic soluble forms of amyloid-beta rapidly increases structural plasticity
possibly allowing functional recovery of neural circuits.
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Introduction
Compelling evidence from rare familial cases of Alzheimer disease (AD) caused by alterations
in the amyloid precursor protein or presenilin 1, which affects its cleavage, support the theory
that amyloid-β (Aβ) processing and aggregation is central to the pathogenesis of AD [30].
Plaque deposition is an early event in the disease process, however plaque burden does not
correlate well with cognitive decline unlike synapse loss and neurofibrillary tangle pathology
[14,36]. Thus there is a pressing search for the link between amyloid and cognitive decline.
Recent data support the idea that synaptotoxicity is mediated by soluble, oligomeric forms of
Aβ [5,13,34], which may provide such a link.
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Work in several mouse models of plaque deposition has shown a decrease in dendritic spine
density near plaques [20,26,37,39]. This decrease is greatest near plaques and spine density
increases to approximately 75% of control levels at distances of greater than 50 μm from the
plaque surface [37,38], likely reflecting the local concentrations of soluble, plaque-associated
synaptotoxic molecules. We recently demonstrated that in the Tg2576 model, loss of spines is
due to a decrease in stability of spines near plaques. Spine formation and elimination were
observed over one hour and more spines were eliminated near plaques in Tg2576 mice than in
control cortex or young Tg2576 animals [38]. Spine loss near plaques could potentially be
associated with the presence of soluble forms of Aβ, or with other phenomena such as the
presence of activated astrocytes and microglia. In organotypic culture, addition of oligomeric
Aβ causes rapid spine loss involving activation of NMDA receptors, calcineurin, and cofilin
[31]. Removal of both NMDA receptors and AMPA receptors has also been implicated in
Aβ induced spine loss in culture [13,34].
To examine whether soluble forms of Aβ contribute to plaque-associated spine loss in vivo,
we observed spine dynamics acutely after application of a neutralizing antibody. It has been
well established that anti Aβ antibodies can clear plaques [2,23], restore neuritic architecture
[3,23], and prevent behavioral changes in APP transgenic mice [7], but these events occur over
days to weeks. By contrast, our current data suggest an acute therapeutic effect of Aβ
neutralizing antibodies, strongly implicating soluble Aβ species as toxic to dendritic spines in
vivo.
Materials and Methods
Animals and surgery
PDAPP animals transgenic for human amyloid precursor protein with the familial Alzheimer
disease associated V717F mutation [10] and non-transgenic littermate controls were used for
this study. Mice were 15–19 months of age and had substantial plaque pathology. For surgeries
and imaging, mice were anesthetized with avertin (1.3% 2,2,2-tribromoethanol, 0.8% tert-
pentylalcohol; 250 mg/kg). Green fluorescent dextrans (3000mw Alexa-488, 50 μg/μL in PBS
– molecular probes) were injected into primary somatosensory cortex. The animal recovered
for 3–5 days to allow dextrans to fill neurons. The day before cranial window implantation,
methoxy X-O4 was injected (4 mg/kg i.p., generously provided by Dr William Klunk,
University of Pittsburg) to label amyloid plaques [16]. The next day, a temporary cranial
window was installed as described previously [1,23,33,37]. Texas Red dextran (70,000 Daltons
molecular weight, 12.5 mg/mL in sterile PBS, Molecular Probes, Eugene OR) was injected
into a lateral tail vein to provide a fluorescent angiogram. An initial set of images of dextran-
filled dendrites and plaques were obtained, then the temporary coverslip was removed and a 1
mg/mL solution containing Alexa 594 labeled anti-Abeta antibody (3D6; n=3 control, 5
PDAPP mice) or anti human tau antibody (16B5; n=4 control, 5 PDAPP mice) was applied
topically to the surface of the brain (dura resected) for 20 minutes (antibodies supplied by Elan,
San Francisco, CA). The brain was then washed with PBS and a glass coverslip cemented in
place before a second set of images were obtained on the multiphoton microscope. All animal
work was approved by institutional committees and conformed to NIH guidelines.
Multiphoton imaging and image analysis
Anesthetized animals with a cranial window were placed in a specialized stage on a BioRad
1024ES multiphoton microscope mounted on an Olympus Optical BX50WI upright
microscope (Olympus, Tokyo, Japan). An Olympus 20x dipping objective with 0.95 numerical
aperture was used to collect images. A mode-locked titanium-sapphire laser (Maitai; Spectra-
physics, Freemont, CA) generated 800nm excitation, and three photomultiplier tubes
(Hamamatsu; Ichinocho, Japan) collected emitted light in the following ranges: 380–480nm,
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500–540nm, and 560–650nm. To avoid photodamage, the lowest laser power that could discern
all spines was used. Each dendrite observed was imaged at an initial time point using a 10x
optical zoom for a final magnification of 200x. A z-stack of images was acquired with an inter-
slice interval of 0.5 μm. Dendrites were re-imaged under the same conditions one hour after
antibody treatment and in some cases, 1 day after treatment.
To correct for artifacts introduced by breathing and heartbeat, image stacks from the
multiphoton microscope were aligned and deconvolved using Autodeblur software
(AutoQuant; Watervliet, NY). Folders were coded to blind the observer and dendrites were
analyzed in green channel images. Dendrites that could be followed for more than 20 microns
and had more than 3 spines were defined as spiny and counted manually using Image J (free
software from the NIH http://rsb.info.nih.gov/ij/download.html). For illustration, Neuron
Studio (free software from the Computational Neurobiology and Imaging Center at Mount
Sinai School of Medicine was used to semi-automatically detect neurites and spines for
reconstruction (http://www.mssm.edu/cnic/tools.html).
Postmortem analysis of Axonal alterations and plaque burden
Animals were euthanized at least 1 day following antibody treatment with an overdose of
avertin (400 mg/kg i.p.) and brains collected into 4% paraformaldehyde containing 15%
glycerol as a cryoprotectant. Brains were sectioned coronally at 50 μm on a freezing microtome
(Leica, Germany) and every 10th section used for immunostaining. Axons were labeled by
staining with primary antibody SMI312 (1:1000 in 1 % NGS in Tris-buffered saline, Covance
Research Products, Inc., Berkely, CA) and secondary antibody anti-mouse IgG conjugated to
Cy3 dye (1:200 in 1 % NGS in Tris-buffered saline, Jackson ImmunoResearch, West Grove,
PA). Plaques were labeled on these sections with Thioflavine-S (0.05% in 50% ethanol).
For axon analysis, the outer 200 μm of cortex in the area treated with antibody (the area under
the window) was sampled at 100% on every 10th section and photomicrographs of axons and
plaques taken using an upright Olympus BX51 (Olympus, Denmark) fluorescence microscope
with a DP70 camera. Axonal curvature and plaque-associated dystrophic axons were analyzed
using Image J software. The curvature ratio was calculated for axonal segments > 20 μm in
length by dividing the curvilinear length of the axon by the straight line length of the process
[6,11,18,23]. Distance from the measured axon segment to the closest senile plaque (if present)
or a phantom plaque for the non transgenic group was measured at three points – from each
end and the midpoint of the segment and the average distance was taken from these three
measurements. Axons that were closer than 50 μm to the plaque were defined as being close
to the plaque and others as far from the plaque. To count dystrophies per plaque, SMI312
positive swellings within the plaque area larger than 6 μm2 were counted as dystrophic axons
and the average number of dystrophies per plaque calculated.
For plaque burden estimation, another series of every 10th section was immunostained with
anti abeta antibody (10D5, Elan) and an HRP conjugated secondary developed with DAB
precipitation. The outer 200 μm of cortex in the area treated with antibody was sampled at
100% and plaque staining automatically detected using BioQuant software (BioQuant,
Nashville, TN) to give percent area occupied by plaques (plaque burden) and individual plaque
sizes.
Statistics
Normality of datasets was assessed using a Kolmogorov-Smirnov test. Normal data (spine
density) were analyzed using 2-way ANOVAs. For axonal dystrophy/plaque data and dendrite
and axonal curvature (which were not normally distributed), a Mann-Whitney test was used to
compare groups. To analyze spine formation and elimination (also not normal distributions),
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each dendrite was grouped by whether the percent elimination (and separately formation) of
spines was above or below the upper quartile of the control distribution. Contingency table
analysis was then used to compare transgenic dendrite segments to the control group as in a
previous study [38].
Results
Plaque-associated dendritic pathology in PDAPP cortex
Dendritic spine density is reduced near plaques in several mouse models [20,26,37,39]. Here
we measured linear spine density in layer II–III of primary somatosensory cortex (apical
branches of layer 3 and 5 pyramidal neurons filled with fluorescent dextrans) in PDAPP and
control animals. We found that at baseline (before antibody treatment) PDAPP mice have
reduced spine density in cortex compared to control animals (n=1201 spines on 126 dendrites
in all groups: ANOVA with genotype as independent variable F[1,122]=12.214, p=0.0007).
This loss is exacerbated near plaques; PDAPP dendrites within 50 μm of a plaque edge exhibit
a 27% reduction in linear spine density compared to control dendrites and a 17% decrease
compared to dendrites further than 50 μm from a plaque in PDAPP brain (ANOVA with
genotype as independent variable categorized by distance from the nearest plaque < or > 50
μm, cell <50 F[1,58]=5.346, p=0.0243, Fig 1).
Previous work has shown that both axons and dendrites curve around plaques in mouse models
and in AD brain [6,17,18,21,23] and that passive immunization can lead to normalization of
dendritic morphologies within several days [23]. We therefore also examined the baseline (pre-
treatment) trajectory of spiny dendrites (filled with fluorescent dextrans) in control and PDAPP
cortex both near and far from dense plaques (labeled with methoxy X-O4). We confirmed that
spiny dendrites are significantly more curved in plaque bearing PDAPP mice than control
animals and in PDAPP cortex, dendrites are more curved within 50 μm of a plaque edge (Fig
1, control vs transgenic Mann-Whitney test p<0.05, PDAPP near vs far from plaque Mann-
Whitney test p<0.05).
Structural plasticity increases rapidly in response to antibody treatment
The above results confirm that plaque-associated dendritic spine loss occurs in aged PDAPP
cortex. Previous work in the Tg2576 mouse model showed an impairment in spine stability
near plaques underlying the loss of spines [38]. To test whether removing soluble Aβ can
rapidly rescue abnormalities in spine plasticity in PDAPP mice, we treated animals with topical
application of either an anti-Aβ antibody or an anti human tau antibody (as a negative control)
and observed structural plasticity of dendritic spines over one hour. Application of anti-Aβ
antibody 3D6 conjugated to alexa fluor 594 shows labeling of dense plaques, diffuse plaques,
and cerebral amyloid angiopathy within the superficial layers of cortex (labeled antibody could
be detected at least 100 μm deep in all cases). Application of anti human tau antibody 16B5
also labeled with alexa fluor 594 did not result in any red labeling of structures after one hour,
indicating that the negative control antibody does not bind amyloid, as expected (Fig 2).
Structural plasticity of individual spines was assessed over one hour in control and PDAPP
animals treated with either 3D6 or 16B5 antibody (758 spines on 79 dendrite segments followed
over 1 hour). In non-transgenic animals, a small fraction of spines (less than 5% of the total
spines examined) were either formed or eliminated over one hour. When soluble Aβ was
neutralized using 3D6 antibody in PDAPP animals, spine formation far from plaques was
significantly increased compared to control levels (Chi squared p=0.0177, Fig 3). This indicates
that structural plasticity increases in response to antibody treatment and demonstrates that
immunotherapy has remarkably rapid effects on dendritic spine plasticity.
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One hour after treatment with either 16B5 or 3D6, PDAPP animals still have reduced mean
dendritic spine density compared to control animals (Fig 4, ANOVA genotype F[1,137]=10.77,
p=0.0013). Despite the rapid effects of 3D6 treatment on spine plasticity, there is not an overall
effect of treatment on mean spine density since the number of new spines formed in one hour
is so small (ANOVA treatment F[1,137]=4.9×10−4, p=0.98).
Plasticity effects precede gross morphological recovery
To determine the effects of passive immunotherapy on plaque burden, axon curvature, and
axonal dystrophies associated with plaques, brains were collected post-mortem and
immunostaining performed to label plaques or axons. Plaque burden in the PDAPP mice was
highly variable. At one day post-treatment, there is no clearance of dense, ThioS positive
plaques as assessed cross-sectionally. Mice treated with 3D6 had an average of 0.068 ± 0.082%
ThioS positive plaque burden in the cortical area under the window, while animals treated with
the control antibody 16B5 had 0.120% ± 0.11% plaque burden. Similarly, the diffuse plaque
burden was variable but showed no recovery 1 day after treatment (3.40 ± 6.02% in 3D6 treated
PDAPP animals, 0.93 ± 1.52% in 16B5 treated PDAPP animals). Non-transgenic animals had
0% dense and diffuse plaque burdens as expected.
There is also no rescue of axonal curvature near plaques one day after antibody treatment (Fig
5). In non-transgenic animals, the curvature ratio was 1.029 in 16B5 treated animals and 1.035
in 3D6 treated animals (no effect of treatment, Mann-Whitney test p>0.05). PDAPP animals
from both treatment groups had significantly curvier axons than control animals (Mann-
Whitney test p<0.01). In PDAPP animals treated with 16B5, the curvature ratio was 1.043
within 50 μm of a plaque edge and 1.021 farther from plaques (significantly curvier near
plaques Mann-Whitney p<0.01). In those PDAPP animals treated with 3D6, the curvature ratio
was 1.050 within 50 μm of a plaque edge and 1.014 further from plaques (significantly curvier
near plaques Mann-Whitney p<0.01). There was similarly no reduction in the mean number
of dystrophic axons associated with each plaque. We would expect normalization of axonal
trajectory to occur within several days of immunotherapy based on previous work [23,25]. This
experiment indicates that it takes more than 1 day for significant plaque clearance and recovery
of axonal perturbations, although effects on spine plasticity can be detected after only 1 hour.
Discussion
Structural plasticity of dendritic spines is implicated in learning and memory. In particular,
spines have been reported to be formed or enlarged with long-term potentiation and to shrink
or disappear with long term depression over a time course of minutes to hours [24,27,28,40].
Exposure to enriched environments, which enhances performance on behavioral tests even in
the context of neurodegeneration, is also associated with new spine formation (reviewed by
[35]). In Alzheimer’s disease, cognitive decline is associated with synapse loss and synapse
loss precedes neuron death (reviewed by [36]). Is Aβ the toxic moiety that causes spine loss,
or do Aβ deposits have a local toxic environment due to free radicals, activated glia, or other
phenomena? We hypothesized that soluble Aβ directly impairs spine stability and tested this
by acutely neutralizing soluble Aβ with an antibody. Since synapses and spines are plastic
structures, even in the adult and aging brain, it is important to investigate their potential for
recovery in animal models to know whether targeting prevention of spine loss or enhancing
spine plasticity are worthwhile therapeutic targets.
In mouse models, both active and passive immunization strategies have been used successfully
to remove amyloid pathology from the brain. Immunization of plaque-bearing mice with
amyloid beta peptide decreases plaque load [29] and rescues behavioral deficits [15]. Treating
mice systemically with anti amyloid beta antibodies also decreases plaque deposition and
restores behavioral deficits [2,12]. Even one dose of antibody topically applied to the brain
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clears diffuse plaques and causes recovery of neurite trajectory within days[1,23]. Whether
immunotherapy can ameliorate synaptic changes with removal of soluble Aβ, before dense
plaques are cleared, was previously unknown.
We used the PDAPP mouse model of plaque formation to study the effects of removing soluble
Aβ on dendritic spine plasticity. In this model, overexpression of the human amyloid precursor
protein gene with the V717F mutation associated with familial Alzheimer’s disease causes
plaque formation, synapse and dendrite loss, and memory and learning deficits [4,8–10]. In
several mouse models that develop plaque pathology, including PDAPP mice, dendritic spines
are lost, particularly near dense plaques [26,37,39]. We previously showed that plaque-
associated spine loss is due to an imbalance in the structural plasticity of dendritic spines with
more spines being eliminated near plaques than formed [38]. Knowing that plaque formation
causes neurite curvature and dystrophy formation within several days [25] and that these
abnormalities can also clear over days after antibody treatment [23] led us to speculate that
removing soluble Aβ with topical antibody treatment could act even more quickly on plasticity
of dendritic spines which occurs more rapidly than changes in neurites (on the order of minutes
to hours).
We tested the hypothesis that soluble Aβ causes disrupted dendritic spine plasticity using in
vivo multiphoton imaging by observing spiny dendrites before treatment and one hour after
antibody treatment. We found that antibody treatment causes an increase in structural plasticity
in PDAPP animals within 1 hour, before there is any evidence of plaque clearance or recovery
of neurite trajectory. We propose that this is due to removing soluble, probably oligomeric
forms of Aβ that have been previously shown to be synaptotoxic in organotypic slice culture
experiments [31,32]. Experiments using peripheral administration of antibodies to Aβ have
shown behavioural improvements within one to 14 days, without concomitant changes in
soluble Aβ levels as detected by ELISA [7,19,22]. For example, three i.p. injections of an
antibody specific to oligomeric Aβ ameliorated behavioral deficits in 7–10 days without
clearing plaques, which strongly indicates that despite no change in soluble Aβ levels as
measured by ELISA, removal of oligomeric Aβ from the brain has beneficial effects on
cognition [5,22]. It should be noted that these rapid effects were observed using an experimental
protocol much more intensive than clinical trials of passive immunization. We topically applied
a concentrated solution of the anti-Aβ antibody 3D6 directly to the brain between acquiring
images of dendritic spines. The dye-labeled antibody was observed bound to plaques and
amyloid angiopathy, but the concentrated solution contained an excess of antibody which was
available to bind soluble Aβ, which we suggest prevents its synaptotoxic effects.
These data indicate that soluble Aβ contributes to impaired dendritic spine plasticity and
synapse loss in this model of AD and further that passive immunotherapy has the potential to
enhance structural plasticity very rapidly.
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Figure 1.
PDAPP animals exhibit dendritic curvature and dendritic spine loss near plaques. Before
antibody treatment, spiny dendrites (green) were observed in control (a) and PDAPP animals
(b,c). Near plaques (blue), spiny dendrites were significantly curvier than those farther from
plaques and curvier than dendrites in control animals (Mann-Whitney test control vs PDAPP
and PDAPP <50 μm from plaque vs >50 μm from plaque, both p<0.05). Curvature ratios of
individual spiny dendrite segments are plotted in (d). The arrow in (b) shows a particularly
curved dendrite near a plaque. Dendritic spines are also lost near plaques in PDAPP mice (e *
p<0.01 ANOVA). The arrowhead in (c) points to a dendrite that becomes less spiny as it
approaches the plaque. Scale bar 10 μm.
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Figure 2.
Treatment with AlexaFlour 594 conjugated 3D6 labels amyloid pathology in PDAPP cortex.
Low resolution images of PDAPP brain treated with labeled 3D6 (a) show cerebral amyloid
angiopathy (arrowhead) dense plaques (large arrows), and diffuse amyloid (small arrows) are
labeled red after treatment. No labeling was observed in either non-transgenic control animals
treated with labeled 3D6 (b) or in PDAPP animals treated with labeled 16B5, an antibody to
human tau which should not be present in mouse brain (c). High resolution images of PDAPP
brain treated with AlexaFlour 594 conjugated 3D6 shows that plaques are labeled 1 hour after
treatment but not before antibody is applied (d). Neurites are filled with dextrans (green) and
dense plaques are labeled with methoxy XO4 (blue). Scale bars 50 μm (a), 10 μm (b–d)
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Figure 3.
Structural plasticity increases with antibody treatment. Individual dendritic spines (n=758)
were followed before treatment and one hour after antibody application. New spines were
occasionally observed after one hour (arrow, a), and some spines were eliminated within one
hour (arrow, b). Reconstruction of dendrites (blue) and spine heads (green) highlights the
formation and elimination. The percent formation and elimination for each dendritic segment
were compared to the upper quartile for non-transgenic % formation and elimination using
contingency table analysis. With this analysis, we observe that significantly more spines are
formed distant from plaques in PDAPP animals one hour after 3D6 treatment compared to
control animals (Chi squared p=0.0177, c). Thus structural plasticity increases rapidly
following anti Aβ antibody treatment but not control antibody treatment. Scale bar 2 μm.
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Figure 4.
The average number of dendritic spines per micron of spiny dendrite length for each group
(control dendrite segments, PDAPP dendrite segments within 50 μm of a plaque, and PDAPP
dendrites far from plaques) was unchanged one hour after antibody treatment (a). Following
individual dendritic segments over one hour and in some cases 1 day (b) shows no great changes
in spine density over these time periods as would be expected since spine formation and
elimination are very rare events. * p < 0.05 post-hoc one way ANOVA.
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Figure 5.
Axonal curvature in PDAPP mice near plaques does not recover within 1 day of antibody
treatment. Axonal neurofilament was stained with smi312 (red) to measure axon curvature near
and far from ThioS labeled plaques (blue). Arrows show curvy dendrites and the arrowhead
shows smi312 positive plaque-associated dystrophies persist for 1 day after 3D6 treatment.
Scale bar 20 μm.
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